Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial by Jiang, Zefei, Prof, Li, Wei, Prof, Hu, Xichun, Prof, Zhang, Qingyuan, Prof, Sun, Tao, Prof, Cui, Shude, Prof, Wang, Shusen, Prof, Ouyang, Quchang, Prof, Yin, Yongmei, Prof, Geng, Cuizhi, Prof, Tong, Zhongsheng, Prof, Cheng, Ying, Prof, Pan, Yueyin, Prof, Sun, Yuping, MD, Wang, Hong, MD, Ouyang, Tao, Prof, Gu, Kangsheng, Prof, Feng, Jifeng, Prof, Wang, Xiaojia, Prof, Wang, Shubin, Prof, Liu, Tianshu, Prof, Gao, Jinghua, MD, Cristofanilli, Massimo, Prof, Ning, Zhiqiang, MD, Lu, Xianping, PhD

Get full text